linrodostat-mesylate

Description: Linrodostat mesylate (formerly known as BMS-986205 mesylate, ONO-7701 mesylate and F001287 mesylate) is a novel, potent, orally bioactive and selective inhibitor of IDO (indoleamine 2, 3-dioxygenase 1) with potential anticancer activities. It is licensed by Flexus Inc. to Bristol-Myers Squibb for clinical development. This compound appears to act as an irreversible inhibitor of high potency (ca.2 nmol/L) with superior pharmacokinetics relative to epacadostat and navoximod. In 2015, BMS-986205 entered a phase I/II study in melanoma patients as monotherapy and in combination with nivolumab (NCT02658890). An interim report noted the compound was well tolerated in patients. A second phase I study of the same combination is being conducted in various other types of advanced cancer patients (NCT03192943).

References: AACR; Cancer Res. 2017; 77 (13 Suppl): Abstract nr CT116.; Cancer Discov. 2018 Jan; 8(1):OF3.

Related CAS #: 1923833-60-6 (free base)